ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACRS vs GERN // 10Y YIELD & FRED MACRO BETA

Aclaris Therapeutics Inc. (NASDAQ) VS. Geron Corporation (NASDAQ) • 15-METRIC TALLY: ACRS 3 — GERN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRS VS. GERN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACRS GERN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -20.20% -14.80 GERN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.04% -18.27% +10.23 ACRS /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -58.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ACRS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.2 32.4 +8.80 ACRS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $559.4M $596.9M -$37.6M GERN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACRS REV GERN REV ACRS GROSS % GERN GROSS % ACRS FCF GERN FCF
FY 2025 $7.8M $192.0M 73.3% — -$47.2M -$111.0M
FY 2024 $18.7M $486.4M 85.1% — -$20.2M -$219.3M
FY 2023 $31.2M $237.0K — — -$78.3M -$167.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRS // BETA —
GERN // BETA —